Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
about
Lumiracoxib does not affect the ex vivo antiplatelet aggregation activity of low-dose aspirin in healthy subjectsCyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerveNon-steroidal anti-inflammatory drugs with different cyclooxygenase inhibitory profiles that prevent aberrant crypt foci formation but vary in acute gastrotoxicity in a rat model.Signaling pathways modulated by fish oil in salt-sensitive hypertensionViscum album exerts anti-inflammatory effect by selectively inhibiting cytokine-induced expression of cyclooxygenase-2.Tolerance of firocoxib in dogs with osteoarthritis during 90 days.Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems.Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.The omega-3 fatty acid docosahexaenoate attenuates endothelial cyclooxygenase-2 induction through both NADP(H) oxidase and PKC epsilon inhibition.COX-2 inhibition: a possible role in the management of prostate cancer?Tissue prostanoids as biomarkers for chemoprevention of colorectal neoplasia: correlation between prostanoid synthesis and clinical response in familial adenomatous polyposisLong-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease.Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies.Systematic review and meta-analysis of COX-2 expression and polymorphisms in prostate cancer.Breaking the cycle: the role of omega-3 polyunsaturated fatty acids in inflammation-driven cancers.Prostaglandin-endoperoxide synthase 2 (PTGS2) rs20417 polymorphism and prostate cancer risk: a meta analysis.Cyclooxygenase-2 induction by arsenite is through a nuclear factor of activated T-cell-dependent pathway and plays an antiapoptotic role in Beas-2B cells.Phospholipase D isozymes mediate epigallocatechin gallate-induced cyclooxygenase-2 expression in astrocyte cells.Participation of COX-1 and COX-2 in the contractile effect of phenylephrine in prepubescent and old rats.Anti-cancer effect of low dose of celecoxib may be associated with lnc-SCD-1:13 and lnc-PTMS-1:3 but not COX-2 in NCI-N87 cells.Different cell kinetic changes in rat stomach cancer after treatment with celecoxib or indomethacin: implications on chemopreventionEndothelins stimulate expression of cyclooxygenase 2 in rat cultured astrocytes.Increased expression of cyclooxygenase-2 protein during rat hepatocarcinogenesis caused by a choline-deficient, L-amino acid-defined diet and chemopreventive efficacy of a specific inhibitor, nimesulide.Oxidative stress in HIV Infection and Alcohol Use: Role of Redox Signals in Modulation of Lipid Rafts and ABC-Transporters.Inhibition of cyclooxygenase-2 sensitizes lung cancer cells to radiation-induced apoptosis.Evaluation of benzothiophene carboxamides as analgesics and anti-inflammatory agents.Nickel compounds render anti-apoptotic effect to human bronchial epithelial Beas-2B cells by induction of cyclooxygenase-2 through an IKKbeta/p65-dependent and IKKalpha- and p50-independent pathway.Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2.Expression of cyclooxygenase-2 and its correlation with vasogenic brain edema in human intracranial meningiomas.Synthesis, cyclooxygenase inhibition, anti-inflammatory evaluation and ulcerogenic liability of new 1-phenylpyrazolo[3,4-d]pyrimidine derivatives.
P2860
Q28192026-2023961F-C7EC-4CF6-BA81-65E374B29B4AQ28361244-5DB8F610-FA9A-4731-B840-221B5A19A583Q31986619-A9E4BF74-86AF-46D7-86E2-A0B0E575D7B4Q33887250-E76E7AD6-2B7F-451A-993D-70EEE05659C4Q34058507-AF0773A7-6246-4182-A903-E45297E0D7BCQ34627504-1342DC6E-075E-4F05-B1C7-4B4EC07B8443Q35044663-21889291-A374-4B88-8B64-BA8E66AE352FQ35048654-731AA478-AF3E-40D4-B7D9-B824BFC50164Q35108122-D59CDF41-26B1-46BF-BEA1-DA3EF8DBBC93Q36740041-CCAD706C-5559-41F0-A0E8-C8FF6DEA8AB9Q37272575-35A2B7C2-BB73-4C7B-9095-DFE542AC0391Q37376934-F9EBE956-7A70-471B-944A-1CA270B1EE5AQ37820728-35C29BA2-9D96-4D5B-B5B9-624BB1D4FCBBQ38051084-37BA8F12-36A2-4EAF-9B0C-C10C3BAA459BQ38237483-05C03D41-8338-4478-9BA7-D01DDA851BB3Q38907143-2CF43AD7-0072-4DA7-8BB3-CA1DE2BDF86FQ40261258-62853631-E2CE-4223-89AC-94075CBF5B65Q40542760-F760B0F0-F7C5-4DB9-8DF7-BAAFC7279238Q40997761-7117FD21-140D-4FF0-B77E-F086F4C6D32CQ41143541-D15D220C-4ED6-4CB8-8EDD-9F79C8C6BAF8Q42017681-FC18229B-E231-4FA9-AE35-638A3FF29F57Q42476710-5ECABEDB-CF27-4438-95E8-D5B126D63CEFQ43901522-DF1D5451-72A2-4099-982F-7FCC20655501Q46262611-DD86A180-3650-4A60-B491-D740F05D72E3Q47141515-D8C1B42E-D2AC-4D1A-AB43-5F94972ED257Q52648838-5A266363-362D-4AC9-9C41-A2F920093430Q53341929-6CAC5CF5-9461-40DA-92FD-4FB1D21FFE8DQ53342780-D91829F7-ED42-40B8-812B-217C8337A8BEQ53457621-45B03B5F-6606-4042-83C6-03D3DA2DE484Q53762520-193303D9-BDD8-4E4F-973E-166E843FDF8C
P2860
Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Distinct isoforms (COX-1 and C ...... and therapeutic implications.
@en
type
label
Distinct isoforms (COX-1 and C ...... and therapeutic implications.
@en
prefLabel
Distinct isoforms (COX-1 and C ...... and therapeutic implications.
@en
P2860
P1476
Distinct isoforms (COX-1 and C ...... and therapeutic implications.
@en
P2093
Engelhardt G
P2860
P356
10.1111/J.1472-8206.1996.TB00144.X
P577
1996-01-01T00:00:00Z